Renovorx highlights new human pharmacokinetic data abstract at sso 2025 annual meeting

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing innovative targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared drug-delivery device, announced today that a new human pharmacokinetic (pk) data abstract was presented at the society of surgical oncology (sso) 2025 annual meeting on march 27 – 29, 2025 in tampa, fl: eposter p379. the abstract provides new human pk data relevant to r.
RNXT Ratings Summary
RNXT Quant Ranking